Comparative analysis of the cost-effectiveness and implementation of lung cancer screening with LDCT in the US and EU

Principal Investigator

Name
Tanya Rajabi

Degrees
B.S.

Institution
Semmelweis University

Position Title
Visiting Scholar

Email
tanya.rajabi@gmail.com

About this CDAS Project

Study
NLST (Learn more about this study)

Project ID
NLST-968

Initial CDAS Request Approval
Oct 11, 2022

Title
Comparative analysis of the cost-effectiveness and implementation of lung cancer screening with LDCT in the US and EU

Summary
Trials have proven that LDCT screening for lung cancer can reduce lung cancer mortality. Yet, questions remain on routine screening's cost-effectiveness and best implementation practices. The EU guidelines and processes for screening vary from those in the US. Thus, we believe that conducting a comprehensive comparative analysis of lung cancer LDCT screening strategies between the US and EU would provide insight on methods for improving its cost-effectiveness and implementation in both jurisdictions.
More specifically, a Markov cohort model depicting patient screening pathways and assessing cost-effectiveness has been created at Semmelweis University. We propose to update this model with the data from the NLST. Doing so will allow for the comparison of the implementation and cost-effectiveness of screening strategies between the US and EU.

Aims

1. Assess the cost-effectiveness of various lung cancer screening strategies.
2. Compare cost-effectiveness of strategies employed by the US and EU to identify both clinically efficient and cost-effective screening practices.

Collaborators

Zoltan Voko (MD, MSc, PhD, DSC), Semmelweis University Center for Health Technology Assessment
Balazs Nagy (MSc, PhD, DrHabil), Semmelweis University Center for Health Technology Assessment